AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
33.42
+0.30 (+0.91%)
At close: 4:02PM EST

33.34 -0.08 (-0.22%)
After hours: 4:07PM EST

Stock chart is not supported by your current browser
Previous Close33.12
Open33.34
Bid0.00 x 0
Ask0.00 x 0
Day's Range33.28 - 33.49
52 Week Range26.51 - 35.60
Volume2,217,041
Avg. Volume3,668,165
Market Cap81.583B
Beta0.65
PE Ratio (TTM)21.92
EPS (TTM)1.52
Earnings DateN/A
Forward Dividend & Yield0.90 (2.70%)
Ex-Dividend Date2017-08-09
1y Target Est39.45
Trade prices are not sourced from all markets
  • Capital Cubeyesterday

    ETFs with exposure to AstraZeneca Plc : December 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AstraZeneca Plc Here are 5 ETFs with the largest exposure to AZN-US. Comparing the performance and risk of AstraZeneca Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • 3 High-Yield Dividend Stocks to Buy in 2018
    Motley Foolyesterday

    3 High-Yield Dividend Stocks to Buy in 2018

    These 3 Big Pharma stocks may be worth adding to your portfolio in 2018.

  • Business Wire2 days ago

    AstraZeneca’s CALQUENCE® (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukemia Trials

    AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial and updated results from the Phase I/II ACE-CL-001 clinical trial that are evaluating acalabrutinib alone and in combination for the treatment of chronic lymphocytic leukemia in multiple treatment settings.

  • Business Wire3 days ago

    AstraZeneca’s CALQUENCE® (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial

    AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration accelerated approval of CALQUENCE® .

  • Why Clovis' Good News In Ovarian Cancer Prodded These Rivals Down
    Investor's Business Daily6 days ago

    Why Clovis' Good News In Ovarian Cancer Prodded These Rivals Down

    Clovis rose Wednesday to the detriment of Tesaro and AstraZeneca after the FDA accepted its application for expanded use of its PARP inhibitor known as Rubraca.

  • Novo Nordisk's Semaglutide Gets FDA Approval for Diabetes
    Zacks6 days ago

    Novo Nordisk's Semaglutide Gets FDA Approval for Diabetes

    Novo Nordisk (NVO) announced that the FDA approved semaglutide, which is a once-weekly injection approved to improve glycaemic control in adults with type II diabetes mellitus.

  • Business Wire7 days ago

    AstraZeneca to Highlight Its Commitment to Blood Cancers at the 2017 American Society of Hematology Annual Meeting

    AstraZeneca, along with Acerta Pharma, its hematology research and development center of excellence, and MedImmune, its global biologics research and development arm, will highlight significant progress in blood cancer research at the 59th 2017 American Society of Hematology Annual Meeting & Exhibition in Atlanta.

  • A Deadly Drug Cocktail Shines a Light on an AstraZeneca Blockbuster
    Bloomberg7 days ago

    A Deadly Drug Cocktail Shines a Light on an AstraZeneca Blockbuster

    Taking Seroquel with methadone can be fatal. Did the drugmaker’s warnings fall short?

  • Barrons.com7 days ago

    [$$] AstraZeneca Sells $10.7 Million in Albireo Stock

    AstraZeneca has halved its investment in Albireo Pharma. A subsidiary of AstraZeneca (ticker: AZN), AstraZeneca AB, sold 500,000 Albireo (ALBO) shares for $10.7 million, or $21.40 each on Dec. 1. AstraZeneca ...

  • FDA approves diabetes drug that also helps with weight loss
    Associated Press7 days ago

    FDA approves diabetes drug that also helps with weight loss

    TRENTON, N.J. (AP) — U.S. regulators on Tuesday approved a new diabetes drug that reduces blood sugar levels and also helps people lose significant weight.

  • Barrons.com7 days ago

    [$$] AstraZeneca Sells $6.6M in G1 Therapeutics Stock

    G1 Therapeutics, a clinical-stage oncology company, announced a collaboration with AstraZeneca Nov. 28. The pact will evaluate AstraZeneca’s (AZN) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) in combination with G1’s (GTHX) oral CDK4/6 inhibitor G1T38 for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). The press release didn’t mention that AstraZeneca, through its MedImmune Ventures subsidiary, is a significant shareholder in G1 nor that MedImmune Ventures has been selling G1 shares.

  • AstraZeneca's COPD Drug Succeeds in Label Expansion Study
    Zacks7 days ago

    AstraZeneca's COPD Drug Succeeds in Label Expansion Study

    AstraZeneca (AZN) releases positive top-line data from a phase IV study, evaluating label expansion of Tudorza for chronic obstructive pulmonary disease with cardiovascular risk factors.

  • ACCESSWIRE8 days ago

    Blog Exposure - FDA Approves Eli Lilly's Taltz(R) for the Treatment of Active PsA

    Stock Monitor: AstraZeneca Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 05, 2017 / Active-Investors issued a free report on Eli Lilly and Co. (NYSE: LLY ), which is readily accessible upon ...

  • Market Realist9 days ago

    Merck’s Diabetes Portfolio in 3Q17

    The combined revenues of Merck's (MRK) Januvia and Janumet in 3Q17 was $1.52 billion, a 2% decline compared to $1.55 billion in 3Q16, mainly due to lower sales of Janumet.

  • 50,000 New Drug Tests Among Brexit Worries for Pharma Companies
    Bloomberg9 days ago

    50,000 New Drug Tests Among Brexit Worries for Pharma Companies

    Global drugmakers from Johnson & Johnson to AstraZeneca Plc warned that potential trade and regulatory hurdles may burden them with a host of additional costs after Britain leaves the European Union.

  • Market Realist11 days ago

    Gauging Novartis’s Valuation This November

    Novartis saw revenues of ~$12.4 billion and EPS of $1.29 for 3Q17, which represents a 2% YoY rise, compared with its revenues of ~$12.1 billion in 3Q16.

  • Benzinga11 days ago

    FDA Decisions In November: The Month In Review

    Rounding out a month marked mostly by positive decisions, FDA announced its approval late for Sublocade, a once-monthly injectable buprenorphine product for the treatment of opioid addiction. U.K.-listed ...

  • What Does AstraZeneca PLC’s (LSE:AZN) Share Price Indicate?
    Simply Wall St.13 days ago

    What Does AstraZeneca PLC’s (LSE:AZN) Share Price Indicate?

    AstraZeneca PLC (LSE:AZN) saw significant share price volatility over the past couple of months on the LSE, rising to the highs of £51.8 and falling to the lows of £45.74.Read More...

  • Business Wire13 days ago

    Celebrity Trainer and Author Bob Harper Teams up with AstraZeneca to Connect with Fellow Heart Attack Survivors

    Bob Harper, celebrity personal trainer, author and heart attack survivor, is teaming up with AstraZeneca to help people like him who have experienced a heart attack share their stories to educate and inspire others.

  • Capital Cube13 days ago

    ETFs with exposure to AstraZeneca Plc : November 29, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AstraZeneca Plc Here are 5 ETFs with the largest exposure to AZN-US. Comparing the performance and risk of AstraZeneca Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA
    Zacks13 days ago

    AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA

    AstraZeneca's (AZN) Marketing Authorisation Application for label expansion of Tagrisso has been accepted by the European Medicines Agency.

  • Market Realist14 days ago

    Nektar Therapeutics Raised Its Revenue Guidance for 2017

    After the collaboration with Eli Lilly for investigational drug NKTR-358, Nektar Therapeutics (NKTR) increased its 2017 revenue projections to $250 million–$255 million.

  • American City Business Journals14 days ago

    RTP company lands work with AstraZeneca

    Research Triangle Park-based G1 Therapeutics (GTHX) – which raised more than $108 million in its initial public offering earlier this year – has landed work with global biopharmaceutical behemoth AstraZeneca. According to G1, it “will sponsor and conduct the Phase 1b/2 study in collaboration with AstraZeneca.” However, financial terms of the collaboration and resulting study – expected to commence in the first quarter of next year – are not being disclosed.

  • AstraZeneca Files for Label Expansion of Tagrisso in Japan
    Zacks14 days ago

    AstraZeneca Files for Label Expansion of Tagrisso in Japan

    AstraZeneca (AZN) files a regulatory application in Japan to expand the label of Tagrisso for first-line treatment of patients with non-small cell lung cancer.

  • American City Business Journals16 days ago

    AstraZeneca forms joint venture in China

    AstraZeneca said Monday it has formed a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to create a stand-alone company in China to discover, develop and commercialize potential new medicines. The new company, Dizal Pharmaceutical, will be equally owned by AstraZeneca and FIIF, which is managed by the private equity management firm SDIC Fund Management Co. “AstraZeneca has a long-standing and strong commitment to China, which we are reinforcing today with this ground-breaking joint venture,” said Pascal Soriot, CEO of AstraZeneca.